

# PROGRESS

## In The Management Of Cystic Fibrosis



**creon**<sup>®</sup>   
pancreatin

---

**RIGHT ON TARGET – RIGHT FROM THE START**

---

**Prescribing Information – Presentation:** Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

**Contra-indications, Warnings, etc:** Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. **Warnings:** Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

**duphar** Further information is available from:  
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.

CRA/PEI/1/89



Making sure Ventolin gets through to the younger generation



**VENTODISKS**

(Salbutamol BP)



Ventodisks (Salbutamol BP). **Abridged Prescribing Information** (Please refer to full data sheet before prescribing.) **Uses:** Treatment and prophylaxis of acute and chronic bronchospasm. **Dosage and administration:** *Adults:* 400 micrograms as single dose or three to four times daily. *Children:* 200 micrograms as single dose or three to four times daily. **Contra-indications:** Threatened abortion during first or second trimester. Hypersensitivity. **Precautions:** If previously effective dose lasts less than three hours, seek medical advice. Caution in patients with thyrotoxicosis. Avoid use with non-selective beta-blockers. Hypokalaemia may occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Serum potassium levels should be monitored in such situations. **Pregnancy:** Avoid unnecessary use during early pregnancy. Only consider if expected benefit outweighs possible risks. **Lactation:** Salbutamol likely to

be secreted in breast milk. Effect on neonate unknown. Balance risks against benefits. **Side effects:** Mild tremor, headache occur rarely. Very rarely — transient muscle cramps and hypersensitivity reactions. Potentially serious hypokalaemia may result from  $B_2$ -agonist therapy. Paradoxical bronchospasm could occur — substitute alternative therapy. **Presentation and Basic NHS cost:** Pack of 14 Ventodisks each containing 8 x 200 micrograms Salbutamol BP (as sulphate) — light blue or 8 x 400 micrograms Salbutamol BP (as sulphate) — dark blue, together with a Ventolin Diskhaler. For inhalation. £7.11 and £12.02. Refill pack of 14 x 8 Ventodisks only. 200 micrograms, £6.54; 400 micrograms, £11.45. **Product licence numbers:** Ventodisks 200 micrograms 0045/0134, Ventodisks 400 micrograms 0045/0135.




ALLEN & HANBURYS

Further information is available on request from: Allen & Hanburys Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT  
Ventodisks should only be used with a Ventolin Diskhaler. Diskhaler, Ventodisks and Ventolin are trade marks

# RSV POSITIVE?

## USE VIRAZID<sup>®</sup> EARLY

Ribavirin



## YOU CAN TREAT THE INFECTION NOT JUST THE SYMPTOMS

### Prescribing Information ▼

#### Indications

Virazid is indicated in the treatment of infants and children with severe respiratory syncytial virus bronchiolitis.

#### Dosage

Treatment is carried out using a small particle aerosol generator (SPAG) for 12-18 hours per day for at least 3 and no more than 7 days. The concentration of ribavirin in the reservoir is 20mg/ml in the SPAG unit and the average concentration for a 7 hour period is 0.19mg/l of air.

#### Presentation

Virazid is a sterile lyophilised powder of ribavirin to be reconstituted for aerosol administration. Each 100ml glass vial contains 6g of ribavirin and, when reconstituted to the correct volume of 300ml with Water for Injections BP, will

contain 20mg/ml ribavirin at a pH of approximately 5.5.

#### Contra-Indications

Ribavirin is contra-indicated in females who are or may become pregnant and it should be noted that ribavirin can be detected in human blood even four weeks after oral administration has ceased.

#### Precautions

In infants requiring assisted ventilation, Virazid should only be used when there is constant monitoring of both patients and equipment.

#### Side Effects

Several serious adverse events occurred in severely ill infants with life-threatening underlying disease many of whom required

assisted ventilation. These events included worsening of respiratory status, bacterial pneumonia and pneumothorax. The role of ribavirin aerosol in these events has not been determined.

Anaemia has been reported with oral and intravenous administration but no such incidents have been reported with aerosol administration. Reticulocytosis has been reported with aerosol use.

#### Warnings

Precipitation of the drug in respiratory equipment and consequent accumulation of fluid in the tubing has caused difficulties for patients requiring assisted ventilation.

In infants requiring assisted ventilation Virazid should only be used when there is constant monitoring of both patients and equipment.

Directions for use during assisted ventilation are given in the SPAG manual which should be read carefully before such administration.

Full prescribing information is available upon request.

▼ Special reporting to the CSM required.

Basic NHS Price: 1 x 6g vial £195.

Product Licence Number : 4657/0004

Product Licence Holder : Viratek Inc. USA

Supplied By : Britannia Pharmaceuticals Ltd  
Forum House  
41-51 Brighton Road  
Redhill, Surrey,  
RH1 6YS

European Journal of

# Pediatrics

Incorporating

Acta Paediatrica Belgica

and

Helvetica Paediatrica Acta

**Volume 150 No. 12 1991**

**The pioneers of pediatric medicine**  
823

## Review

**Small-intestinal abnormalities in  
cystic fibrosis patients**  
E. Eggermont, K. De Boeck 824

## Cardiology

**Left ventricular thrombus  
in a 2-year-old boy with  
cardiomyopathy: lysis with  
recombinant tissue-type  
plasminogen activator**  
O. N. Krogmann, R. v. Kries,  
S. Rammos, H. H. Kramer,  
M. Bourgeois 829

## Gastroenterology/Hepatology

**Documented latent coeliac  
disease in a child with insulin-  
dependent diabetes mellitus**  
C. Catassi, G. Natalini, I. M. Rättsch,  
O. Gabrielli, G. V. Coppa, P. L. Giorgi  
832

## Hematology/Oncology

**Optic gliomas in children with  
neurofibromatosis type 1**  
A. M. Lund, F. Skovby 835

**Cytoplasmic granules in  
leukaemic cells of the  
cerebrospinal fluid in a child with  
non-granular acute lymphocytic  
leukaemia**

T. Hanada, I. Ono, N. Moriyama,  
K. Koike 839

**Transcobalamin II deficiency:  
case report and review of the  
literature**

Y. Kaikov, L. D. Wadsworth,  
C. A. Hall, P. C. J. Rogers 841

## Immunology/Allergology

**Cord serum IgE and early  
detection of the atopic  
phenotype: suitable for routine  
screening?**

H. S. Varonier, G. C. Lacourt,  
A. Assimacopoulos 844

## Medical genetics

**Cartilage hair hypoplasia  
in infancy: a misleading  
chondrodysplasia**

M. Le Merrer, P. Maroteaux  
847

## Metabolic diseases

**Chronic pancreatitis in a child  
with glycogen storage disease  
type 1**

M. Kikuchi, K. Hasegawa, I. Handa,  
M. Watabe, K. Narisawa, K. Tada  
852

## Neonatology

**Ipratropium bromide for  
symptomatic preterm infants**  
B. Yuksel, A. Greenough 854

## Letters to the editors

**Mitral valve and tricuspid valve  
prolapse in Melnick-Needles  
syndrome**

G. Krüger, K. Schumacher, F. Erfurt,  
L. Pelz 858

**An infant having Potter facies  
without pulmonary hypoplasia  
after prolonged oligohydramnios  
due to a placental mass**

M. Ohyama 859

**Simultaneous epiglottitis siblings**

B. Zimmer, K. Vogel, D. Schranz  
859

**Acute caffeine poisoning  
in a child**

P. G. Jorens, J. M. Van Hauwaert,  
M. I. Selala, P. J. C. Schepens 860

## Abstracts

**The Summer Meeting of the  
Scottish Paediatric Society,  
Aberdeen, 31 May 1991 861**

*Acknowledgement to our reviewers*  
865

*Contents of Volume 150*

*Index of key words*

*Indexed in Current Contents*



Springer International

### Subscription information

Volume 150 (12 issues) will appear in 1991. Information about obtaining back volumes and microform editions available upon request.

**North America.** Annual subscription rate: approx. US \$ 1060.00 (single issue price approx. \$ 102.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to:

Springer-Verlag New York Inc.  
Service Center Secaucus  
44 Hartz Way  
Secaucus, NJ 07094, USA  
Tel. (201) 348-4033  
Telex 023 125 994  
FAX (201) 348-4505

**All other countries.** Annual subscription rate: DM 1598.00 plus carriage charges; Federal Republic of Germany: DM 27.61 incl. value added tax; all other countries: DM 60.60 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 125.40, India DM 96.60, Australia/New Zealand DM 141.00. Airmail delivery to all other countries is available upon request. Volume price: DM 1598.00, single issue price: DM 159.80 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag  
Heidelberger Platz 3, 1000 Berlin 33, FRG  
Tel. (0)30/8207-0, Telex 183319  
FAX (0)30/8214091



# Controlling seizures, changing lives

**Established Efficacy - In Adults and Children**  
Over 16 thousand patient years to date.<sup>(1)</sup>

In uncontrolled epilepsy > 50% reduction  
of seizures in approximately 50% of patients with some  
becoming seizure free.<sup>(2)</sup>

**Serum Monitoring not required**  
Therapeutically significant interactions with other  
antiepilepsy drugs are unlikely.<sup>(3,4,5)</sup>

**Defined mode of action**

**SABRIL<sup>®</sup>**  
VIGABATRIN

Specific GABA-transaminase inhibition  
for uncontrolled epilepsy

**MARION  
MERRELL  
DOW**

Marion Merrell Dow Limited, Lakeside House, Stockley Park, Uxbridge, Middlesex UB11 1BE  
Trademarks: Marion, Merrell, Dow, Sabril.

Abridged Prescribing information and references appear on the following page

## Abridged Prescribing Information

### SABRIL Tablets

**Presentation:** White, tablets with a breakline marked SABRIL, each containing 500mg vigabatrin.

**Uses:** Indications: Treatment of epilepsy not controlled by other antiepileptic drugs.

**Dosage and Administration:** Oral administration once or twice daily added to the patient's current therapeutic regimen.

**Adults:** Recommended starting dose 2g/day. Increased or decreased in 0.5g or 1.0g increments depending upon clinical response and tolerability. Maximum 4g/day. There is no direct correlation between plasma concentration and efficacy. **Children:** Recommended starting dose 1g/day in ages 3-9 years and 2g/day if older.

**Elderly:** Consider dose reduction in patients with impaired renal function.

**Contra-indications, Precautions, Warnings etc.**

**Use in pregnancy and lactation:** Contra-indicated.

**Precautions:** Abrupt withdrawal may lead to rebound seizures. Caution in patients with history of psychosis or behavioural problems. Caution in elderly patients, particularly creatinine clearance below 60ml/min. Reduce dose and monitor closely for adverse events.

**Warnings:** Vigabatrin causes intramyelinic oedema in the brain white matter tracts of animals but there is no evidence of this in man. However, monitor patients for neurological changes. See the full product data sheet.

**Effects on driving ability:** Drowsiness has been seen and patients should be warned.

**Side effects:** Are mainly CNS related. Aggression and psychosis have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor. Other reported events: drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache and less commonly confusion, memory disturbance and vision complaints; also weight gain and minor gastrointestinal side-effects. Also in children excitation and agitation. Some patients may experience an increase in seizure frequency with vigabatrin, particularly those with myoclonic seizures. Tests have not revealed evidence of neurotoxicity in humans. Lab data do not indicate renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed. Chronic treatment may lead to a slight decrease in haemoglobin.

**Drug Interactions:** Are unlikely. A gradual reduction of about 20% in plasma phenytoin concentration has been observed.

No clinically significant interactions with carbamazepine, phenobarbitone or sodium valproate.

**Legal Category:** POM

**Package Quantities:** Blister strips of 10 in cartons of 100.

**Product Licence Number:** PL 4425/0098

**NHS Price:** £46.00

**Date of Preparation:** January 1992.

You must refer to the full prescribing information before administering Sabril. Further information including full product data sheet is available from the Licence Holder:

Marion Merrell Dow Ltd., Lakeside House, Stockley Park, Uxbridge, Middlesex. UB11 1BE.

#### References:

1. Worldwide Sales Data
2. Mumford JP. Br J Clin Pract 1988; 42 (Suppl 61): 7-9
3. Tartara A. et al. Epilepsia 1986;27:717-723
4. Tassinari CA et al, Arch Neurol 1987;44:907-910
5. Rimmer EM, Richens A. Lancet 1984;1:189-190

**MARION  
MERRELL  
DOW**



Trademarks: Marion, Merrell, Dow, Sabril. Job No.SAB/AD/1291

# ABC OF CHILD ABUSE

**BMJ**

EDITED BY ROY MEADOW

Cruelty to children is common; every week at least four children in Britain die as a result of abuse or neglect, and in England alone nearly 40 000 children are listed on child protection ("at risk") registers. The *ABC of Child Abuse* gives clear guidance on how to recognise child abuse—including the more recently identified forms such as sexual and emotional abuse and factitious illnesses—and on what to do when you suspect or know that it is occurring.


Edited by Professor Roy Meadow, head of the department of paediatrics and child health, St James's University Hospital, Leeds, the book has contributions from paediatricians, child psychiatrists, a police surgeon, a social worker, a lawyer, and a victim. It should be read by everyone concerned with the care of children.

Inland £10.95; Abroad £13.00  
BMA members:  
Inland £9.95; Abroad £12.00  
including postage by air abroad

Please enclose payment with order  
or send us full details of your ACCESS,  
MASTERCARD or AMERICAN EXPRESS  
credit card.

ORDER FROM British Medical Journal, PO Box 295, London WC1H 9TE or any leading medical bookseller

# While you're trying to make it better, make it bearable.



# Zofran

ondansetron ▼

**Prescribing information:** Uses Nausea and vomiting due to chemotherapy or radiotherapy. **Dosage Emetogenic chemotherapy and radiotherapy:** Either, 8mg i.v. as a slow injection immediately before treatment, or 8mg orally 1 to 2 hours before treatment, followed by 8mg orally twelve-hourly. To protect against delayed emesis, Zofran should be continued orally, 8mg twice daily for up to 5 days. **Highly emetogenic chemotherapy:** A single dose of 8mg i.v. as a slow injection immediately before chemotherapy, followed by 8mg orally twice daily for up to 5 days to protect against delayed emesis. The efficacy of Zofran over the first 24 hours of highly emetogenic chemotherapy may be enhanced by the addition of a single i.v. dose of 20mg dexamethasone immediately before treatment. Alternatively, higher doses of Zofran may be beneficial, up to 32mg depending on the severity of the emetogenic challenge. **Children:** A single i.v. dose of 5mg/m<sup>2</sup> immediately before chemotherapy, followed by 4mg orally twelve-hourly for up to 5 days. **Elderly and patients with renal impairment:** No alteration of dosage, dosing frequency or route of administration is required over 65 years or with renal impairment. **Patients with hepatic impairment:** In patients with moderate or severe hepatic impairment, a total daily dosage of 8mg should not be exceeded. Contra-

**indications** Hypersensitivity to components. **Precautions** Pregnancy or lactation. **Side effects** Headache, constipation, a warm or flushing sensation in the head or epigastrium. Occasional transient rises in aminotransferases. Rare, immediate hypersensitivity reactions (see data sheet). **Presentations** Zofran Injection ampoules containing 4mg ondansetron in 2ml aqueous solution or 8mg ondansetron in 4ml aqueous solution (Product licence number 0004/0375, 4mg x 5 ampoules £52.50; 8mg x 5 ampoules £75). Zofran 4mg Tablets each containing 4mg ondansetron (Product licence number 0004/0376, 4mg x 30 tablets £187.50). Zofran 8mg Tablets each containing 8mg ondansetron (Product licence number 0004/0377, 8mg x 10 tablets £90). **Product licence holder** Glaxo Operations U.K. Limited, Greenford, Middlesex UB6 0HE. Zofran is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Tel: 081-990 9444.



CALL FOR PAPERS

# Quality in Health Care

EDITOR: **FIONA MOSS**  
AUDIT SPECIALIST & RESPIRATORY PHYSICIAN

ASSOCIATE EDITORS: **Steve Nixon**, Surgeon, **Richard Baker**, GP, **Michael Maresh**, Obstetrician  
**Allison Kitson**, Director of RCN Standards of Care Project  
**Richard Thomson**, Public Health and **Chris West**, District General Manager

**QUALITY IN HEALTH CARE** is a new quarterly journal being launched in March 1992, by the BMJ to reflect and report initiatives to improve quality of health care, from everybody involved in health care.

The Journal aims to monitor:

- The relationship between clinical and medical audit and quality assurance programmes
- The development of clinical and medical audit as local activities and as larger national initiatives
- The integration of medical audit into medical practice
- The impact of medical and clinical audit on postgraduate and undergraduate training and education
- The relationship between management and quality initiatives

The editorial board includes, clinicians from a variety of specialties, together with representatives from management, nursing, other health care professions, quality assurance programmes, public health and medical education.

## RESEARCH AREAS

- The development and testing of quality measures
- The development of outcome measures
- Studies on the appropriateness and effectiveness of medical and other clinical interventions
- Commissioned articles will include critical overviews of evidence on which medical and other clinical interventions are based. Opposing views will be sought and debated.

## SUBMISSION

Papers should be submitted, in accordance with Instructions to Authors as set out in the BMJ, to:

Fiona Moss, Editor,  
Quality in Health Care,  
North West Thames Regional Health  
Authority, 40 Eastbourne Terrace,  
Paddington, London W2 3QR.  
Telephone: 071 262 8011 ext. 3098  
Fax: 071 258 0530

To receive more information and a sample copy complete the form below:

### Order Form

#### QUALITY IN HEALTH CARE

PUBLICATION: Quarterly

ISSN: 0963-8172

Please tick

- Please send me more information
- Please send me *Instructions to Authors*
- Please send me a sample copy

Signature \_\_\_\_\_

Name (Capitals) \_\_\_\_\_

Address \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date \_\_\_\_\_

Send orders to: British Medical Journal, BMA House, Tavistock Square, London. WC1H 9JR.



# How is no longer a problem — but there's still which and why

The microcomputer revolution has made powerful machines and highly complex programs generally available. This means that users of statistical techniques need no longer be concerned with the arithmetical and algebraic details — the software will take care of all that. What is vital, however, is to understand the ideas and the basic principles of statistical analysis. In *Medical Statistics on Microcomputers* R A Brown and J Swanson Beck show how to get the best use out of microcomputers when analysing data, particularly in the pathology laboratory. They explain the rational basis of various widely applicable statistical methods and also indicate their limitations so that you can make an informed choice. Chapters include:

- Data handling
- Analysis of data from one or two groups
- Comparison of several groups
- Analysis of categorical data
- Statistical methods for diagnostic tests.

UK £8.95; Abroad £10.50; US\$25.00  
BMA members: £8.45 or £10.00  
ACP members: US\$21.00

## Let the *BMJ* guide you through statistics:

**STATISTICS WITH CONFIDENCE** — Confidence intervals and statistical guidelines. Martin J Gardner, Douglas G Altman.

Many medical journals, including the *British Medical Journal*, now expect scientific papers submitted to them to contain confidence intervals when appropriate. Why? what are they? and how do you calculate them? *Statistics With Confidence* tells you. A clear explanation of the reasons for using confidence intervals is followed by detailed presentation of methods of calculation, including numerous worked examples and specially compiled tables. To make things even easier, a computer programme, Confidence Interval Analysis (CIA), for calculating confidence intervals, has been specially designed by Martin Gardner and details are available from the Publishing Department, *British Medical Journal* (or the American College of Physicians).

UK £7.95; Abroad £9.50; US\$24.00 BMA members £7.45 or £9.00 ACP members US\$19.00

**STATISTICS AT SQUARE ONE** — T D V Swinscow

The statistical testing of data is indispensable in many types of medical investigation and a help on countless occasions in clinical practice. This book provides step by step instruction. Subjects covered include standard deviation,  $X^2$  tests, t tests, non-parametric tests, and correlation. The book includes sections on Fisher's exact probability test and rank correlation. Methods specially adapted to pocket calculators.

UK £3.95; Abroad £5.00; US\$13.00 BMA members £3.45 or £4.50 ACP members US\$11.00

**STATISTICS IN PRACTICE** — Sheila M Gore, Douglas G Altman

No doctor can afford to ignore statistics: most modern medical research uses statistics. This important and authoritative book provides clear information on designing studies, applying statistical techniques, and interpreting studies that use statistics. It can be easily understood by those with no statistical training and should be read by all those who want to keep abreast of new developments.

UK £8.95; Abroad £11.00; US\$23.00 BMA members £7.95 or £10.00 ACP members US\$19.00

**EPIDEMIOLOGY FOR THE UNINITIATED** — Geoffrey Rose, D J P Barker

Epidemiology has its own techniques of data collection and interpretation and its necessary jargon of technical terms, and in *Epidemiology For The Uninitiated* the authors guide the novice expertly through the theory and practical pitfalls. The second edition of this popular *BMJ* handbook has been revised to include further details of epidemiological methods and some of their more dramatic applications, such as the investigations on the Spanish cooking oil epidemic, and AIDS.

UK £4.95; Abroad £6.00; US\$14.00 BMA members £4.45 or £5.50 ACP members US\$12.00

ORDER FORM

BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9TE, any leading bookseller, or the *BMJ* bookshop.

North America only: AMERICAN COLLEGE OF PHYSICIANS, P.O. Box 7777-R-0270, Philadelphia, PA 19175. In Pennsylvania, add 6% sales tax. Residents of Canada add 7% GST.

Please send me \_\_\_\_\_ copy/ies of the following *BMJ* books \_\_\_\_\_

Membership no. \_\_\_\_\_

I enclose a cheque for \_\_\_\_\_ made payable to **British Medical Journal** (North America: American College of Physicians)

Debit my  Visa  American Express  Mastercard \_\_\_\_\_

Card No. \_\_\_\_\_

Expiry Date \_\_\_\_\_ Signature \_\_\_\_\_

NAME \_\_\_\_\_


ADDRESS \_\_\_\_\_

POSTCODE \_\_\_\_\_

All prices include postage, by air abroad.

Endotracheal tube	
Length (cm)	Internal diameter (mm)
18-21	7.5-8.0
18	7.0
17	6.5
16	6.0
15	5.5
14	5.0
13	4.5
12	4.0
10	3.5-3.5

### Paediatric resuscitation chart



Adrenaline (ml of 1/10 000) intravenous or endotracheal	0.5	1	2	3	4	5
Atropine (mg) intravenous or endotracheal	0.1	0.2	0.4	0.6	0.6	0.6
Bicarbonate (ml of 8.4%) intravenous	5	10	20	30	40	50
Calcium chloride (mmol)* intravenous	1	2	4	6	8	10
Diazepam (mg) intravenous per rectum	1.25 2.5	2.5 5	5 10	7.5 10	10 —	10 —
Glucose (ml of 50%) intravenous	10	20	40	60	80	100
Lignocaine (mg) intravenous or endotracheal	5	10	20	30	40	50
Salbutamol (µg) intravenous	25	50	100	150	200	250
Initial DC defibrillation (J)	10	20	40	60	80	100
Initial fluid infusion in hypovolaemic shock (ml)	50	100	200	300	400	500

\* One millilitre calcium chloride 1 mmol/ml = 1.5 ml calcium chloride 10% = 4.5 ml calcium gluconate 10%

## A child is dying: what do you do?

Resuscitating children is different from resuscitating adults—and more difficult. Because cardiorespiratory arrest in children is uncommon each doctor's experience of handling it is limited, and there is a tendency to forget the recommended drug doses; also, because children come in so many different sizes it is hard to judge the correct dose, especially if you do not know the child's weight. Yet delay or inaccuracy in treatment might be fatal. **The Paediatric Resuscitation Chart**, devised by Dr Peter Oakley and based on the guidelines of the Resuscitation Council (UK), gives you at a glance the essential information for making rapid and accurate decisions. The chart is available as an A2 size poster or a pocket sized postcard.

Poster: UK £3.50; Abroad £4.50 including packing and postage, by air abroad.

Single copies of a postcard version of the chart are available, free of charge, on receipt of an A5 stamped addressed envelope (16cm x 24cm; 6in x 9in). Bulk orders please write to the Book Department.

Credit cards are accepted: ACCESS, VISA, AMERICAN EXPRESS (please give full details)

**BMJ**

BRITISH MEDICAL JOURNAL, BMA HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR

## BASIC MOLECULAR AND CELL BIOLOGY

## An excellent beginner's guide

The extraordinary technical developments in molecular biology over the past few years, and the equally rapid advances in understanding of cell biology, will almost certainly result in far reaching changes in medical research and practice. In this collection of articles experts in molecular and cell biology provide the background information to give clinicians an insight into the way in which the medical sciences may be moving over the next few years and into the exciting possibilities opening up for the treatment of genetic disorders, cancer, and the common illnesses of Western society such as degenerative vascular disease and diabetes.

UK £6.95; Abroad £8.00  
(BMA members £6.45 or £7.50)  
including postage, by air abroad

ORDER YOUR COPY

**NOW**

Available from: **BRITISH MEDICAL JOURNAL**,  
PO Box 295, London WC1H 9TE, medical booksellers  
or the **BMJ** bookshop in **BMA House**

Please send me \_\_\_\_\_ copy/ies of

**BASIC MOLECULAR & CELL BIOLOGY**

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_ POSTCODE \_\_\_\_\_

I enclose \_\_\_\_\_ Please make cheques payable  
to **British Medical Journal**

Debit my credit card (please tick box)

Visa  American Express  Mastercard

Card No \_\_\_\_\_

Card expiry date \_\_\_\_\_

Signature \_\_\_\_\_

BMA Membership No \_\_\_\_\_

Please send me a book catalogue

SEND FOR YOUR  
FREE SAMPLE COPY

# Journal of Medical Genetics

EDITOR: PETER S HARPER

North American Editor: P. Michael Conneally • Cytogenetics Editor: Patricia A. Jacobs  
Molecular Genetics Editor: Kay E. Davies • Reviews Editor: Rodney Harris

**JOURNAL OF MEDICAL GENETICS**, the first to be devoted specifically to medical genetics, is pleased to announce continuing developments, in response to the needs of readers and authors.

### NEW FEATURES FOR 1992

- Half Price Personal Subscriptions for all Members of Major Societies, including European Society for Human Genetics and Clinical Genetics Society
- Change to A4 Format – providing
  - Improved Illustration Quality
  - Faster Publication
- New Literature Update Section
- New Gene Mapping Review Series on Major Chromosomal Regions
- Colour Reproduction

The journal will continue to feature General Reviews, Syndrome of the Month, Conference Reports, Original Papers and Short Reports on all aspects of medical genetics.

### RESEARCH AREAS OF SPECIAL EMPHASIS


- Molecular Genetics and Its Clinical and Cytogenetic Applications
- Dysmorphology and the Delineation of New Syndromes
- Fundamental Aspects of Human Genetics
- Development of Clinical Genetic Services

1991 Subscription Rate: UK & Eire: £126, Overseas £134, USA: \$230

To Order Your Subscription or Sample Copy Please Complete the Order Form Below:

<b>Order Form</b>	
<b>JOURNAL OF MEDICAL GENETICS</b>	Card Number
ISSN: 0022-2593	<input type="text"/>
PUBLICATION: Monthly	<input type="text"/>
SUBSCRIPTION RATE: UK & EIRE: £126	<input type="text"/>
OVERSEAS: £134 USA: \$230	<input type="text"/>
<i>Please tick</i>	Expiry date _____
<input type="checkbox"/> Please enter my subscription, start date _____	Signature _____
<input type="checkbox"/> Please send me a sample copy	<i>(Your signature is essential, especially when paying by credit card)</i>
<input type="checkbox"/> Please send me <i>Instructions to Authors</i>	Name (Capitals) _____
<input type="checkbox"/> I enclose a cheque for _____	Address _____
<i>(Payable to British Medical Journal)</i>	_____
<input type="checkbox"/> I wish to pay by credit card.	_____
AmericaExpress/Visa(Barclaycard)/Mastercard	Date _____
<i>(Delete as appropriate)</i>	
Send orders to: <b>British Medical Journal, BMA House, Tavistock Square, London. WC1H 9JR.</b>	

“Days  
to remember  
... *all my life*”



**Prescribing Information** PenMix® 30/70 Penfill® 100iu/ml (Biphasic Isophane Insulin Injection 30/70), Human Insulin (pyr). **Indications:** The treatment of insulin-requiring diabetics.

**Dosage and Administration:** The dosage is determined by the physician according to the needs of the patient. Given by subcutaneous injection and intended for use in the NovoPen and NovoPen II injection devices only. (See instructions for use of devices). Resuspend before use by agitating up and down.

**Contraindications:** Hypoglycaemia. **Precautions:** Injections of PenMix 30/70 Penfill should be followed by a meal within 30 minutes of administration. A dosage reduction may be required on transfer from bovine or mixed species insulin. Reduction of early warning symptoms of hypoglycaemia may be seen upon tightening control and has been reported by a few patients on transfer from animal source to human insulin. Beta blockers, MAOIs and alcohol may enhance hypoglycaemic effect of insulin. Corticosteroids, thyroid hormones, oral contraceptives may increase insulin requirements. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during second and third trimester. **Side-effects:** Lipodystrophy, insulin resistance and hyper-sensitivity are rarely reported with human insulin.

**Product Licence Number and Basic NHS Price:** PL 4668/0020, 5x1.5ml cartridges £8.10. **Product Licence Holder:** Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Denmark. **Sole Distributor:** Farillon Limited, Ashton Road, Harold Hill, Romford, Essex RM3 8UE.

**Further information is available on request from:** Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk House, Broadfield Park, Brighton Road, Pease Pottage, Crawley, West Sussex RH11 9RT. Telephone: (0293) 613555.

June 1991

\* Registered trade mark of Novo Nordisk A S

**Free supplies of NovoPen II available on request**  
DIAL 100 AND ASK FOR FREEPHONE  
NOVO NORDISK INSULIN

Leading the way in diabetes care




Novo Nordisk

For many patients with diabetes, convenience can matter just as much as control.

That is why PenMix 30/70 Penfill is such an appropriate choice for people of all ages.

PenMix 30/70 Penfill lets them get on with enjoying their lives without the fuss and bother of complex in-syringe insulin mixing and with the added convenience of NovoPen® II.



**PenMix® 30/70 PENFILL®**

Biphasic Isophane Insulin injection.

Human Insulin (pyr)

CONVENIENCE WITH CONTROL  
ALL IN ONE EASY STEP